Biotech Calendar: Key Dates for February
BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for February:
Feb. 2
Ironwood Pharmaceuticals
(IRWD) - Get Report
initial public offering.
Feb 8 - 9
BIO CEO Conference, New York.
Feb. 9
FDA approval decision date for
GlaxoSmithKline
(GSK) - Get Report
and
Xenoport's
(XNPT)
Solzira for restless leg syndrome.
Feb. 10
FDA Oncologic Drug Advisory Committee meeting to discuss
Cell Therapeutics'
(CTIC) - Get Report
lymphoma drug pixantrone. FDA's briefing documents for this meeting likely available Feb. 8 - 9.
Micromet
( MITI) investor/analyst day.
Feb. 11
FDA approval decision date for
Labopharm's
( DDSS) trazadone contramid for major depressive disorder.
Feb. 12
FDA approval decision date for
Cadence Pharmaceuticals'
(CADX)
Acetevance (intravenous acetaminophan) for hospital use.
Feb. 13
FDA approval decision date for
Gilead Sciences'
(GILD) - Get Report
Cayston antibiotic for cystic fibrosis.
Feb. 16-19
Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco
Gilead will be presenting phase II data on its "Quad pill" for HIV.
Feb. 23
FDA advisory panel to review
Salix Pharmaceuticals'
(SLXP)
Xifaxan in hepatic encephalopathy.
Feb 25
ImmunoGen
(IMGN) - Get Report
investor/analyst meeting.
Feb. 28
FDA approval decision date for
Shire's
( SHPGY) velaglucerase in Gaucher's disease.
Ongoing FDA reviews with no firm decision date:
Auxillium Pharmaceuticals
(AUXL)
and
Pfizer's
(PFE) - Get Report
Xiaflex for Dupuytren's Contracture.
Mannkind's
(MNKD) - Get Report
Afresa (inhaled insulin) for diabetes.
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on
.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.